FibroGen, Inc. (FGEN)
NASDAQ$0.318-0.01 (-3.05%)
Market Cap
$33.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
245 of 918
Rank in Industry
140 of 522
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
FGEN Insider Trading Activity
FGEN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $181,587 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Schoeneck James A | director | 2 | $105,040 | 0 | $0 | $105,040 |
| Wettig Thane | CEO | 1 | $50,663 | 0 | $0 | $50,663 |
| Adib Deyaa | Chief Medical Officer | 1 | $25,884 | 0 | $0 | $25,884 |
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human …
Insider Activity of FibroGen, Inc.
Over the last 12 months, insiders at FibroGen, Inc. have bought $181,587 and sold $0 worth of FibroGen, Inc. stock.
On average, over the past 5 years, insiders at FibroGen, Inc. have bought $325,420 and sold $2.31M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schoeneck James A (director) — $105,040. Wettig Thane (CEO) — $50,663. Adib Deyaa (Chief Medical Officer) — $25,884.
The last purchase of 145,000 shares for transaction amount of $50,663 was made by Wettig Thane (CEO) on 2025‑03‑24.
List of Insider Buy and Sell Transactions, FibroGen, Inc.
| 2025-03-24 | Wettig Thane | CEO | 145,000 0.1361% | $0.35 | $50,663 | -7.29% | ||
| 2025-03-21 | Schoeneck James A | director | 50,000 0.0536% | $0.34 | $17,040 | +8.68% | ||
| 2025-03-20 | Schoeneck James A | director | 250,000 0.2595% | $0.35 | $88,000 | +2.09% | ||
| 2024-06-12 | Adib Deyaa | Chief Medical Officer | 22,123 0.023% | $1.17 | $25,884 | -64.74% | ||
| 2024-03-07 | Wettig Thane | CEO | 50,000 0.0545% | $1.91 | $95,470 | -71.62% | ||
| 2023-09-01 | Sale | Henderson Jeffrey William | director | 2,000 0.002% | $1.03 | $2,060 | -8.40% | |
| 2023-08-04 | Sale | Henderson Jeffrey William | director | 2,000 0.002% | $1.91 | $3,820 | -44.24% | |
| 2023-07-11 | Sale | Henderson Jeffrey William | director | 2,000 0.0021% | $2.69 | $5,380 | -58.61% | |
| 2023-07-07 | Sale | Conterno Enrique A | Chief Executive Officer | 1,880 0.0021% | $2.80 | $5,264 | -58.15% | |
| 2023-06-23 | Sale | Wettig Thane | Chief Commercial Officer | 791 0.0009% | $16.53 | $13,075 | -92.77% | |
| 2023-06-14 | Sale | Chung Christine | SVP, China Operations | 6,250 0.0068% | $16.79 | $104,925 | -92.83% | |
| 2023-06-13 | Sale | Chung Christine | SVP, China Operations | 6,250 0.0066% | $17.60 | $110,000 | -93.28% | |
| 2023-06-09 | Sale | EDWARDS JEFFREY L | director | 7,889 0.0084% | $17.19 | $135,622 | -92.99% | |
| 2023-06-09 | Sale | Blaug Suzanne | director | 8,520 0.0091% | $17.20 | $146,571 | -92.99% | |
| 2023-06-09 | Sale | Cravatt Benjamin | director | 3,944 0.0042% | $17.17 | $67,717 | -92.99% | |
| 2023-06-09 | Sale | Brennan Aoife | director | 4,733 0.0051% | $17.19 | $81,367 | -92.99% | |
| 2023-06-08 | Sale | Henderson Jeffrey William | director | 7,000 0.0073% | $17.45 | $122,185 | -93.31% | |
| 2023-06-08 | Sale | Ho Maykin | director | 8,520 0.0088% | $17.44 | $148,591 | -93.31% | |
| 2023-06-07 | Sale | Conterno Enrique A | Chief Executive Officer | 8,897 0.0093% | $17.04 | $151,583 | -93.02% | |
| 2023-06-07 | Sale | Chung Christine | SVP, China Operations | 3,633 0.0038% | $17.04 | $61,894 | -93.02% |
Total: 483
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Wettig Thane | CEO | 543329 0.5384% | $178,211.91 | 3 | 7 | <0.0001% |
| Schoeneck James A | director | 373722 0.3703% | $122,580.82 | 2 | 8 | |
| Adib Deyaa | Chief Medical Officer | 82123 0.0814% | $26,936.34 | 1 | 0 | |
| Conterno Enrique A | Chief Executive Officer | 374722 0.3713% | $122,908.82 | 2 | 7 | +14.48% |
| Lema Gerald | director | 3500 0.0035% | $1,148.00 | 1 | 0 | +19.61% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $30.51M | |
$22,186,116 | 57 | -43.73% | $36.66M | |
$53,490,060 | 55 | 19.35% | $29.48M | |
$23,895,365 | 34 | -37.28% | $27.3M | |
$20,234,041 | 17 | 2.08% | $36.61M |
FGEN Institutional Investors: Active Positions
| Increased Positions | 25 | +25.51% | 3M | +5.55% |
| Decreased Positions | 38 | -38.78% | 12M | -26.72% |
| New Positions | 11 | New | 746,500 | New |
| Sold Out Positions | 15 | Sold Out | 4M | Sold Out |
| Total Postitions | 85 | -13.27% | 36M | -21.17% |
FGEN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Armistice Capital, Llc | $2,142.00 | 6.73% | 6.8M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,851.00 | 5.82% | 5.88M | -5,385 | -0.09% | 2024-12-31 |
| Primecap Management Co/Ca/ | $1,454.00 | 4.57% | 4.62M | -5M | -53.42% | 2024-12-31 |
| Acadian Asset Management Llc | $1,230.00 | 3.87% | 3.91M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $749.00 | 2.35% | 2.38M | -14,403 | -0.6% | 2024-12-31 |
| 683 Capital Management, Llc | $674.00 | 2.12% | 2.14M | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $428.00 | 1.35% | 1.36M | +605,572 | +80.41% | 2024-12-31 |
| Marshall Wace, Llp | $399.00 | 1.25% | 1.27M | -179,327 | -12.41% | 2024-12-31 |
| Geode Capital Management, Llc | $333.00 | 1.05% | 1.06M | -25,173 | -2.32% | 2024-12-31 |
| Two Sigma Advisers, Lp | $277.00 | 0.87% | 878,400 | +135,600 | +18.25% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.